New strategies for combatting sepsis: the magic bullets missed the mark ... but the search continues.
Despite the high expectations of scientists and industry, multiple clinical trials of anti-endotoxin- and anti-cytokine-based therapies for sepsis have failed to demonstrate benefit. Indeed, in some cases, the agents used were actually harmful to patients. In retrospect, perhaps the therapeutic premises on which these therapies were based were flawed. In the future, a better understanding of sepsis should lead to the development of accurate laboratory and clinical predictors that will identify when, and which, patients can benefit from a given therapy. Much has been learned from the efforts of industry and academia and, hopefully, the search for new therapies for this lethal syndrome will continue.
Quezado
Z M
ZM
Critical Care Medicine Department, National Institutes of Health, Bethesda, MD 20892.
Banks
S M
SM
Natanson
C
C
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors; D004731:Endotoxins / Q000276:immunology; D006801:Humans; D018805:Sepsis / Q000209:etiology / Q000628:therapy*; D012772:Shock, Septic / Q000628:therapy
D000911:Antibodies, Monoclonal; D016207:Cytokines; D004731:Endotoxins